To investigate the potentials of immune-competent subtypes as efficient targets for immune checkpoint inhibitors, we compared the expressions of immune checkpoint genes: PD-1, PD-L1, PD-L2 and CTLA4 which are well-known targets of immune checkpoint inhibitors3 between the subtypes in 7 cancer types. This evidence concerns the gene PDCD1LG2 and cancer.